Monday, December 3, 2018 from 11:30 AM to 1:30 PM EST
Add to Calendar 


Massachusetts Biotechnology Council 

Driving Directions 


Eric Wexler 
Cambridge Biomedical Inc. 

Cambridge Biomedical BTK Occupancy/Immuno Oncology Lunch 

For nearly a decade Cambridge Biomedical has played a role in the development of ImmunoOncology therapies. In understanding multiple roles of BTK our validated BTK Occupancy Assay has supported many biopharma companies.

Bruton’s tyrosine kinase (Btk) is a kinase largely expressed in B cells and myeloid cells and it plays an essential role in the B Cell Receptor (BCR) signaling pathway, often involving involving other members of the Tyrosine Protein Kinase (Tec) family of kinases.

Given the essential role of Btk in the BCR signaling pathway and the normal development and function of B cells, there are several disease indications that have been attributed to abnormal BCR activity. These include autoimmune diseases such as Lupus, MS and RA in which B cells inappropriately break self-tolerance to produce antibodies contributing to the autoimmune disease.  BCR signaling also contributes to several B cell malignancies such as CLL and MCL.  New therapies that target BCR signaling are showing remarkable promise in the clinic.

Small molecule covalent inhibitors of Btk such as ibrutinib and acalabrutinib are available for treatment with other similar molecules in development. Measurement of the pharmacodynamic activity of these inhibitors entail an indirect assay to measure unbound or free Btk and comparing it with the total Btk in patients treated with the drug. Cambridge Biomedical will discuss our experience in the development and validation of assays for total and free Btk measurement in PBMCs.

Maloy M. Mangada, PhD

Dr Mangada is Associate Director of Scientific Services at Cambridge Biomedical and serves as the lead immunologist directing a team of accomplished scientists in the development and

 validation of novel high and low complexity   assays.  He has more than 20 years’   experience with biomarker assay   development, including 15 years of flow   cytometry assay development and validation.   Dr.  Mangada has a PhD in Molecular   Virology,  an MS in Molecular Biology and   Biotechnology  and a BS in Applied Physics.   He undertook a   Post-Doctoral Research   Fellowship, studying   T cell immunology at   the University of   Massachusetts Medical   School.